A new RNA part­ner­ship hunts rare epilep­sies; Ab­b­Vie and I-Mab tack­le CD47

Zo­genix is get­ting a new part­ner as it looks to tack­le rare child­hood seizures.

The Cal­i­for­nia-based biotech, which de­vel­oped and pro­duces the seizure drug Fin­tepla, is team­ing with Tre­vard Bio­sciences to de­vel­op RNA-based gene ther­a­pies for Dravet syn­drome and oth­er ge­net­ic epilep­sies.

Spun out of MIT and ad­vised by David Liu and Bob Langer, Tre­vard is try­ing to use tran­scrip­tion­al RNA to in­crease the ex­pres­sion of healthy copies of the gene be­hind Dravet’s syn­drome in pa­tients and de­crease the ex­pres­sion of the faulty copy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER